Abstract

Background: Alkaline phosphatase (ALP) and albumin (ALB) have been shown to be associated with coronary artery disease (CAD), and it has been reported that alkaline phosphatase-to-albumin ratio (AAR) is associated with the liver damage and poorer prognosis of patients with digestive system malignancy. Moreover, several previous studies showed that there was a higher incidence of malignancy in CAD patients. However, to our knowledge, the relationship between AAR and long-term adverse outcomes in CAD patients after undergoing percutaneous coronary intervention (PCI) has not been investigated. Therefore, we aim to access the relation between AAR and long-term adverse outcomes in post-PCI patients with CAD.Methods: A total of 3378 post-PCI patients with CAD were enrolled in the retrospective Clinical Outcomes and Risk Factors of Patients with Coronary Heart Disease after PCI (CORFCHD-ZZ) study from January 2013 to December 2017. The median duration of follow-up was 37.59 ± 22.24 months. The primary end point was long-term mortality including all-cause mortality (ACM) and cardiac mortality (CM). The secondary end points were major adverse cardiac events (MACEs) and major adverse cardiac and cerebrovascular events (MACCEs).Results: Kaplan–Meier analyses showed that an increased AAR was positively correlated with incidences of long-term ACM (log-rank, P=0.014), CM (log-rank, P=0.011), MACEs (log-rank, P=0.013) and MACCEs (log-rank, P=0.006). Multivariate Cox regression analyses showed that the elevated AAR was an independent predictor of long-term ACM (adjusted HR = 1.488 [1.031–2.149], P=0.034), CM (adjusted HR = 1.837 [1.141–2.959], P=0.012), MACEs (adjusted HR = 1.257 [1.018–1.551], P=0.033) and MACCEs (adjusted HR = 1.237 [1.029–1.486], P=0.024).Conclusion: An elevated AAR is a novel independent predictor of long-term adverse outcomes in CAD patients following PCI.

Highlights

  • Coronary artery disease (CAD) has been a major cause of mortality, and researches on coronary artery disease (CAD) have drawn intense attention worldwide [1]

  • Considering that Alkaline phosphatase (ALP) and ALB are involved in the onset, development and prognosis of CAD, it may be feasible to evaluate the potential value of alkaline phosphatase-to-albumin ratio (AAR) as a biomarker in predicting the adverse outcomes of CAD patients

  • The Receiver operating characteristic (ROC) curve showed that the cut-off value of AAR was 1.77, which divided a total of 3378 CAD patients after undergoing percutaneous coronary intervention (PCI) into two groups: the lower group (AAR < 1.77, n=1676) and the higher group (AAR ≥ 1.77, n=1702)

Read more

Summary

Introduction

Coronary artery disease (CAD) has been a major cause of mortality, and researches on CAD have drawn intense attention worldwide [1]. Several previous studies showed that there was a higher incidence of malignancy in patients with CAD [20,21,22] It is unknown whether AAR is associated with adverse prognosis in CAD patients. To the best of our knowledge, there is no previous study investigating the relation between AAR and long-term adverse outcomes in post-PCI patients with CAD. Alkaline phosphatase (ALP) and albumin (ALB) have been shown to be associated with coronary artery disease (CAD), and it has been reported that alkaline phosphatase-to-albumin ratio (AAR) is associated with the liver damage and poorer prognosis of patients with digestive system malignancy. To our knowledge, the relationship between AAR and long-term adverse outcomes in CAD patients after undergoing percutaneous coronary intervention (PCI) has not been investigated.

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call